Skip to main content

What the FDA labels say about taking them together

Famciclovir and raloxifene

Famciclovir's FDA label of September 17, 2025 names raloxifene in its drug interactions section; the raloxifene labels PlainMeds reads (2) do not name famciclovir. The famciclovir label: “Raloxifene, a potent aldehyde oxidase inhibitor in vitro, could decrease the formation of penciclovir.”

Check it at the source: the famciclovir FDA label on DailyMed (effective September 17, 2025, Macleods Pharmaceuticals Limited); the raloxifene FDA label on DailyMed (effective April 14, 2026, Amneal Pharmaceuticals LLC).

What does the famciclovir label say about raloxifene?

Famciclovir label, drug interactions

Raloxifene, a potent aldehyde oxidase inhibitor in vitro, could decrease the formation of penciclovir.

Source: FDA drug label (Famciclovir), Macleods Pharmaceuticals Limited, effective September 17, 2025 (SPL set eeeee9c4-8566-4100-8ca4-3df936a3365d), via openFDA; the full label on DailyMed

What does the raloxifene label say about famciclovir?

Raloxifene's label (effective April 14, 2026) and its 1 other brand-application label do not name famciclovir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Raloxifene Hydrochloride), Amneal Pharmaceuticals LLC, effective April 14, 2026 (SPL set 3798c70b-a4b0-4811-9788-e4c9cff47ebe), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

9Famciclovir generic labelers
17Raloxifene generic labelers
FamciclovirRaloxifene
Labeled forHerpes and shinglesOsteoporosis, Breast cancer
Boxed warningNoYes
Pharmacy cost (NADAC)$0.214 per tablet 125 mg tablet$0.223 per tablet 60 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?